Moderna announced Thursday it has submitted a request to the Food and Drug Administration for authorization for its two-dose coronavirus vaccine to be used in children ages 6 months to 5 years. The biotechnology company said in March that interim analysis showed "a robust" antibody response after a two-dose series of the COVID-19 drug. "We are proud to share that we have initiated our EUA submission for authorization for our ...